Table 1.

Clinical characteristics of critically ill patients with COVID-19 compared with negative subjects with pneumonia.

	Patients with COVID-19 N = 24 (%)	Patients with pneumonia N = 24 (%)	p value
Demographics
Age, median (IQR)	68 (62–59)	64 (50–71)	0.45
Gender (Male)	17 (71)	14 (61)	0.47
Charlson comorbidity index	4 (4–4)	4 (3–5)	0.78
Hospitalization
Length-of in-hospital stay, median (IQR) days	37 (28–55)	19 (6–30)	< 0.001
Time from hospital admission to respiratory sample, median (IQR) days	25 (12–27)	15 (5–17)	0.15
Time from ICU admission to respiratory sample, median (IQR) days	0 (0–3)	0 (0–5)	0.34
Time from COVID-19 diagnosis to respiratory sample, median (IQR) days	10 (1–16)	4 (1–8)	< 0.005
Time from symptoms onset to respiratory sample, median (IQR) days	18 (11–27)	15 (5–20)	0.14
Time from antimicrobial treatment to respiratory sample, median (IQR) days	2 (0–10)	8 (3–19)	0.45
ICU admission	23 (96)	3 (13)	< 0.001
Mechanical ventilation	24 (100)	6 (25)	< 0.001
Days of mechanical ventilation, median (IQR)	16 (13–23)	3 (2–15)	< 0.001
Time from intubation to respiratory sample, median (IQR) days	9 (3–19)	1 (0–13)	0.04
Total BAL samples (BAL per patients)	118 (5)	51 (2)
Radiological findings
Interstitial pneumonia	24 (100)	9 (37)	< 0.001
Multifocal	0	8 (33)
Single infiltrate/Nodules	0	5 (21)
Cavitating pnuomonia	0	2 (8)
Treatments
Hydroxycholoroquine	24 (100)	1 (4)	< 0.001
Antivirals
Darunavir	3 (12)	0 (0)	< 0.001
Remdesivir	1 (4)	0 (0)
Lopinavir/ritonavir	10 (42)	0 (0)
INF	5 (21)	0 (0)	< 0.001
Tocilizumab	13 (54)	0 (0)	< 0.001
Corticosteroids	10 (42)	3 (13)	0.049
Antibiotics	13 (54)	14 (60)	0.88
BL/BLI	8 (33)	4 (17)	0.31
Cephalosporin	2 (8)	6 (26)	0.13
Carbapenem	3 (12)	2 (9)	0.99
Other	7 (29)	6 (26)	0.83
In-hospital mortality	8 (33)	1 (4)	< 0.001